The Experts below are selected from a list of 123270 Experts worldwide ranked by ideXlab platform
Bruce D. Graham - One of the best experts on this subject based on the ideXlab platform.
-
topical 5 fluorouracil in the management of extensive anal bowen s disease a preferred approach
Diseases of The Colon & Rectum, 2005Co-Authors: Bruce D. Graham, Allen B. Jetmore, Jerry E. Foote, Kirk L ArnoldAbstract:PURPOSE: An alternative approach to anal Bowen's disease was investigated. The use of topical 5 percent 5-Fluorouracil for large lesions and surgical excision of small lesions were evaluated. METHODS: A prospective study was undertaken for anal Bowen's disease in 11 patients over a six-year period. Before therapy all patients underwent anal mapping biopsy and colonoscopy. For one-half circumferential disease or greater, patients underwent topical 5 percent 5-fluorouacil therapy for 16 weeks. For smaller involvement, wide surgical excision was performed. All patients underwent anal mapping biopsy one year after completion of therapy. RESULTS: Of 11 patients, 8 (5 male) received 16 weeks of topical 5 percent 5-fluorouacil therapy. Three patients (3 female) underwent surgical excision for localized disease. All but one patient, who was HIV positive, were free of Bowen's disease one year after completion of therapy. One patient underwent total excision of a residual microinvasive squamous carcinoma after circumferential Bowen's disease had resolved. One patient received eight additional weeks of topical 5-fluorouacil therapy for incomplete resolution. All patients were followed yearly, with a mean follow-up of 39 months and a range of 12 to 74 months. There have been no recurrences. There were no long-term side effects or morbidity from topical 5-fluorouacil or local excision. All colonoscopies were normal. CONCLUSION: Topical 5 percent 5-fluorouacil therapy is a safe and effective method to treat anal Bowen's disease. Wide local excision is appropriate for smaller, isolated areas of disease. Anal Bowen's disease was not associated with colonic or other neoplasms.
-
Topical 5-Fluorouracil in the Management of Extensive Anal Bowen’s Disease: A Preferred Approach
Diseases of the Colon & Rectum, 2005Co-Authors: Bruce D. Graham, Allen B. Jetmore, Jerry E. Foote, L. Kirk ArnoldAbstract:PURPOSE An alternative approach to anal Bowen’s disease was investigated. The use of topical 5 percent 5-Fluorouracil for large lesions and surgical excision of small lesions were evaluated. METHODS A prospective study was undertaken for anal Bowen’s disease in 11 patients over a six-year period. Before therapy all patients underwent anal mapping biopsy and colonoscopy. For one-half circumferential disease or greater, patients underwent topical 5 percent 5-fluorouacil therapy for 16 weeks. For smaller involvement, wide surgical excision was performed. All patients underwent anal mapping biopsy one year after completion of therapy. RESULTS Of 11 patients, 8 (5 male) received 16 weeks of topical 5 percent 5-fluorouacil therapy. Three patients (3 female) underwent surgical excision for localized disease. All but one patient, who was HIV positive, were free of Bowen’s disease one year after completion of therapy. One patient underwent total excision of a residual microinvasive squamous carcinoma after circumferential Bowen’s dis-ease had resolved. One patient received eight additional weeks of topical 5-fluorouacil therapy for incomplete resolution. All patients were followed yearly, with a mean follow-up of 39 months and a range of 12 to 74 months. There have been no recurrences. There were no long-term side effects or morbidity from topical 5-fluorouacil or local excision. All colonoscopies were normal. CONCLUSION Topical 5 percent 5-fluorouacil therapy is a safe and effective method to treat anal Bowen’s disease. Wide local excision is appropriate for smaller, isolated areas of disease. Anal Bowen’s disease was not associated with colonic or other neoplasms.
-
Topical 5-Fluorouracil in the Management of Extensive Anal Bowen’s Disease: A Preferred Approach
Diseases of the Colon & Rectum, 2005Co-Authors: Bruce D. Graham, Allen B. Jetmore, Jerry E. Foote, L. Kirk ArnoldAbstract:PURPOSE An alternative approach to anal Bowen’s disease was investigated. The use of topical 5 percent 5-Fluorouracil for large lesions and surgical excision of small lesions were evaluated. METHODS A prospective study was undertaken for anal Bowen’s disease in 11 patients over a six-year period. Before therapy all patients underwent anal mapping biopsy and colonoscopy. For one-half circumferential disease or greater, patients underwent topical 5 percent 5-fluorouacil therapy for 16 weeks. For smaller involvement, wide surgical excision was performed. All patients underwent anal mapping biopsy one year after completion of therapy. RESULTS Of 11 patients, 8 (5 male) received 16 weeks of topical 5 percent 5-fluorouacil therapy. Three patients (3 female) underwent surgical excision for localized disease. All but one patient, who was HIV positive, were free of Bowen’s disease one year after completion of therapy. One patient underwent total excision of a residual microinvasive squamous carcinoma after circumferential Bowen’s dis-ease had resolved. One patient received eight additional weeks of topical 5-fluorouacil therapy for incomplete resolution. All patients were followed yearly, with a mean follow-up of 39 months and a range of 12 to 74 months. There have been no recurrences. There were no long-term side effects or morbidity from topical 5-fluorouacil or local excision. All colonoscopies were normal. CONCLUSION Topical 5 percent 5-fluorouacil therapy is a safe and effective method to treat anal Bowen’s disease. Wide local excision is appropriate for smaller, isolated areas of disease. Anal Bowen’s disease was not associated with colonic or other neoplasms.
L. Kirk Arnold - One of the best experts on this subject based on the ideXlab platform.
-
Topical 5-Fluorouracil in the Management of Extensive Anal Bowen’s Disease: A Preferred Approach
Diseases of the Colon & Rectum, 2005Co-Authors: Bruce D. Graham, Allen B. Jetmore, Jerry E. Foote, L. Kirk ArnoldAbstract:PURPOSE An alternative approach to anal Bowen’s disease was investigated. The use of topical 5 percent 5-Fluorouracil for large lesions and surgical excision of small lesions were evaluated. METHODS A prospective study was undertaken for anal Bowen’s disease in 11 patients over a six-year period. Before therapy all patients underwent anal mapping biopsy and colonoscopy. For one-half circumferential disease or greater, patients underwent topical 5 percent 5-fluorouacil therapy for 16 weeks. For smaller involvement, wide surgical excision was performed. All patients underwent anal mapping biopsy one year after completion of therapy. RESULTS Of 11 patients, 8 (5 male) received 16 weeks of topical 5 percent 5-fluorouacil therapy. Three patients (3 female) underwent surgical excision for localized disease. All but one patient, who was HIV positive, were free of Bowen’s disease one year after completion of therapy. One patient underwent total excision of a residual microinvasive squamous carcinoma after circumferential Bowen’s dis-ease had resolved. One patient received eight additional weeks of topical 5-fluorouacil therapy for incomplete resolution. All patients were followed yearly, with a mean follow-up of 39 months and a range of 12 to 74 months. There have been no recurrences. There were no long-term side effects or morbidity from topical 5-fluorouacil or local excision. All colonoscopies were normal. CONCLUSION Topical 5 percent 5-fluorouacil therapy is a safe and effective method to treat anal Bowen’s disease. Wide local excision is appropriate for smaller, isolated areas of disease. Anal Bowen’s disease was not associated with colonic or other neoplasms.
-
Topical 5-Fluorouracil in the Management of Extensive Anal Bowen’s Disease: A Preferred Approach
Diseases of the Colon & Rectum, 2005Co-Authors: Bruce D. Graham, Allen B. Jetmore, Jerry E. Foote, L. Kirk ArnoldAbstract:PURPOSE An alternative approach to anal Bowen’s disease was investigated. The use of topical 5 percent 5-Fluorouracil for large lesions and surgical excision of small lesions were evaluated. METHODS A prospective study was undertaken for anal Bowen’s disease in 11 patients over a six-year period. Before therapy all patients underwent anal mapping biopsy and colonoscopy. For one-half circumferential disease or greater, patients underwent topical 5 percent 5-fluorouacil therapy for 16 weeks. For smaller involvement, wide surgical excision was performed. All patients underwent anal mapping biopsy one year after completion of therapy. RESULTS Of 11 patients, 8 (5 male) received 16 weeks of topical 5 percent 5-fluorouacil therapy. Three patients (3 female) underwent surgical excision for localized disease. All but one patient, who was HIV positive, were free of Bowen’s disease one year after completion of therapy. One patient underwent total excision of a residual microinvasive squamous carcinoma after circumferential Bowen’s dis-ease had resolved. One patient received eight additional weeks of topical 5-fluorouacil therapy for incomplete resolution. All patients were followed yearly, with a mean follow-up of 39 months and a range of 12 to 74 months. There have been no recurrences. There were no long-term side effects or morbidity from topical 5-fluorouacil or local excision. All colonoscopies were normal. CONCLUSION Topical 5 percent 5-fluorouacil therapy is a safe and effective method to treat anal Bowen’s disease. Wide local excision is appropriate for smaller, isolated areas of disease. Anal Bowen’s disease was not associated with colonic or other neoplasms.
Allen B. Jetmore - One of the best experts on this subject based on the ideXlab platform.
-
topical 5 fluorouracil in the management of extensive anal bowen s disease a preferred approach
Diseases of The Colon & Rectum, 2005Co-Authors: Bruce D. Graham, Allen B. Jetmore, Jerry E. Foote, Kirk L ArnoldAbstract:PURPOSE: An alternative approach to anal Bowen's disease was investigated. The use of topical 5 percent 5-Fluorouracil for large lesions and surgical excision of small lesions were evaluated. METHODS: A prospective study was undertaken for anal Bowen's disease in 11 patients over a six-year period. Before therapy all patients underwent anal mapping biopsy and colonoscopy. For one-half circumferential disease or greater, patients underwent topical 5 percent 5-fluorouacil therapy for 16 weeks. For smaller involvement, wide surgical excision was performed. All patients underwent anal mapping biopsy one year after completion of therapy. RESULTS: Of 11 patients, 8 (5 male) received 16 weeks of topical 5 percent 5-fluorouacil therapy. Three patients (3 female) underwent surgical excision for localized disease. All but one patient, who was HIV positive, were free of Bowen's disease one year after completion of therapy. One patient underwent total excision of a residual microinvasive squamous carcinoma after circumferential Bowen's disease had resolved. One patient received eight additional weeks of topical 5-fluorouacil therapy for incomplete resolution. All patients were followed yearly, with a mean follow-up of 39 months and a range of 12 to 74 months. There have been no recurrences. There were no long-term side effects or morbidity from topical 5-fluorouacil or local excision. All colonoscopies were normal. CONCLUSION: Topical 5 percent 5-fluorouacil therapy is a safe and effective method to treat anal Bowen's disease. Wide local excision is appropriate for smaller, isolated areas of disease. Anal Bowen's disease was not associated with colonic or other neoplasms.
-
Topical 5-Fluorouracil in the Management of Extensive Anal Bowen’s Disease: A Preferred Approach
Diseases of the Colon & Rectum, 2005Co-Authors: Bruce D. Graham, Allen B. Jetmore, Jerry E. Foote, L. Kirk ArnoldAbstract:PURPOSE An alternative approach to anal Bowen’s disease was investigated. The use of topical 5 percent 5-Fluorouracil for large lesions and surgical excision of small lesions were evaluated. METHODS A prospective study was undertaken for anal Bowen’s disease in 11 patients over a six-year period. Before therapy all patients underwent anal mapping biopsy and colonoscopy. For one-half circumferential disease or greater, patients underwent topical 5 percent 5-fluorouacil therapy for 16 weeks. For smaller involvement, wide surgical excision was performed. All patients underwent anal mapping biopsy one year after completion of therapy. RESULTS Of 11 patients, 8 (5 male) received 16 weeks of topical 5 percent 5-fluorouacil therapy. Three patients (3 female) underwent surgical excision for localized disease. All but one patient, who was HIV positive, were free of Bowen’s disease one year after completion of therapy. One patient underwent total excision of a residual microinvasive squamous carcinoma after circumferential Bowen’s dis-ease had resolved. One patient received eight additional weeks of topical 5-fluorouacil therapy for incomplete resolution. All patients were followed yearly, with a mean follow-up of 39 months and a range of 12 to 74 months. There have been no recurrences. There were no long-term side effects or morbidity from topical 5-fluorouacil or local excision. All colonoscopies were normal. CONCLUSION Topical 5 percent 5-fluorouacil therapy is a safe and effective method to treat anal Bowen’s disease. Wide local excision is appropriate for smaller, isolated areas of disease. Anal Bowen’s disease was not associated with colonic or other neoplasms.
-
Topical 5-Fluorouracil in the Management of Extensive Anal Bowen’s Disease: A Preferred Approach
Diseases of the Colon & Rectum, 2005Co-Authors: Bruce D. Graham, Allen B. Jetmore, Jerry E. Foote, L. Kirk ArnoldAbstract:PURPOSE An alternative approach to anal Bowen’s disease was investigated. The use of topical 5 percent 5-Fluorouracil for large lesions and surgical excision of small lesions were evaluated. METHODS A prospective study was undertaken for anal Bowen’s disease in 11 patients over a six-year period. Before therapy all patients underwent anal mapping biopsy and colonoscopy. For one-half circumferential disease or greater, patients underwent topical 5 percent 5-fluorouacil therapy for 16 weeks. For smaller involvement, wide surgical excision was performed. All patients underwent anal mapping biopsy one year after completion of therapy. RESULTS Of 11 patients, 8 (5 male) received 16 weeks of topical 5 percent 5-fluorouacil therapy. Three patients (3 female) underwent surgical excision for localized disease. All but one patient, who was HIV positive, were free of Bowen’s disease one year after completion of therapy. One patient underwent total excision of a residual microinvasive squamous carcinoma after circumferential Bowen’s dis-ease had resolved. One patient received eight additional weeks of topical 5-fluorouacil therapy for incomplete resolution. All patients were followed yearly, with a mean follow-up of 39 months and a range of 12 to 74 months. There have been no recurrences. There were no long-term side effects or morbidity from topical 5-fluorouacil or local excision. All colonoscopies were normal. CONCLUSION Topical 5 percent 5-fluorouacil therapy is a safe and effective method to treat anal Bowen’s disease. Wide local excision is appropriate for smaller, isolated areas of disease. Anal Bowen’s disease was not associated with colonic or other neoplasms.
Stephen Rimmer - One of the best experts on this subject based on the ideXlab platform.
-
Synthesis and release of 5-Fluorouracil from poly(N-vinylpyrrolidinone) bearing 5-Fluorouracil derivatives.
Journal of controlled release : official journal of the Controlled Release Society, 2002Co-Authors: Zuifang Liu, Stephen RimmerAbstract:1-beta-allyloxycarbonyloxymethyl-5-Fluorouracil (4) and 1,3-bis(beta-allyloxycarbonyloxymethyl)-5-Fluorouracil (5) were synthesised by reacting 5-Fluorouracil with formaldehyde followed by treating the product with isopropenyl chloroformate. The monomers 4 and 5 were copolymerized separately with N-vinylpyrrolidinone to form linear copolymers and cross-linked polymer networks, respectively. The monomer reactivity ratios in the copolymerization of 4 with NVP were evaluated by both linear and non-linear methods and the effect of monomer feed composition on copolymer molecular weight was examined. The degradation of the polymer networks in phosphate buffer (pH 7.4) was investigated. The hydrolytic scission of the carbonate groups resulted in release of 5-Fluorouracil and a decrease in cross-linking density. The time-dependent fractional release of the 5-FU could be fitted by a power relationship with exponents between 0.10 and 0.25.
-
Synthesis and release of 5-Fluorouracil from poly(N-vinylpyrrolidinone) bearing 5-Fluorouracil derivatives.
Journal of Controlled Release, 2002Co-Authors: Zuifang Liu, Stephen RimmerAbstract:Abstract 1-β-Allyloxycarbonyloxymethyl-5-Fluorouracil ( 4 ) and 1,3-bis(β-allyloxycarbonyloxymethyl)-5-Fluorouracil ( 5 ) were synthesised by reacting 5-Fluorouracil with formaldehyde followed by treating the product with isopropenyl chloroformate. The monomers 4 and 5 were copolymerized separately with N -vinylpyrrolidinone to form linear copolymers and cross-linked polymer networks, respectively. The monomer reactivity ratios in the copolymerization of 4 with NVP were evaluated by both linear and non-linear methods and the effect of monomer feed composition on copolymer molecular weight was examined. The degradation of the polymer networks in phosphate buffer (pH 7.4) was investigated. The hydrolytic scission of the carbonate groups resulted in release of 5-Fluorouracil and a decrease in cross-linking density. The time-dependent fractional release of the 5-FU could be fitted by a power relationship with exponents between 0.10 and 0.25.
Jerry E. Foote - One of the best experts on this subject based on the ideXlab platform.
-
topical 5 fluorouracil in the management of extensive anal bowen s disease a preferred approach
Diseases of The Colon & Rectum, 2005Co-Authors: Bruce D. Graham, Allen B. Jetmore, Jerry E. Foote, Kirk L ArnoldAbstract:PURPOSE: An alternative approach to anal Bowen's disease was investigated. The use of topical 5 percent 5-Fluorouracil for large lesions and surgical excision of small lesions were evaluated. METHODS: A prospective study was undertaken for anal Bowen's disease in 11 patients over a six-year period. Before therapy all patients underwent anal mapping biopsy and colonoscopy. For one-half circumferential disease or greater, patients underwent topical 5 percent 5-fluorouacil therapy for 16 weeks. For smaller involvement, wide surgical excision was performed. All patients underwent anal mapping biopsy one year after completion of therapy. RESULTS: Of 11 patients, 8 (5 male) received 16 weeks of topical 5 percent 5-fluorouacil therapy. Three patients (3 female) underwent surgical excision for localized disease. All but one patient, who was HIV positive, were free of Bowen's disease one year after completion of therapy. One patient underwent total excision of a residual microinvasive squamous carcinoma after circumferential Bowen's disease had resolved. One patient received eight additional weeks of topical 5-fluorouacil therapy for incomplete resolution. All patients were followed yearly, with a mean follow-up of 39 months and a range of 12 to 74 months. There have been no recurrences. There were no long-term side effects or morbidity from topical 5-fluorouacil or local excision. All colonoscopies were normal. CONCLUSION: Topical 5 percent 5-fluorouacil therapy is a safe and effective method to treat anal Bowen's disease. Wide local excision is appropriate for smaller, isolated areas of disease. Anal Bowen's disease was not associated with colonic or other neoplasms.
-
Topical 5-Fluorouracil in the Management of Extensive Anal Bowen’s Disease: A Preferred Approach
Diseases of the Colon & Rectum, 2005Co-Authors: Bruce D. Graham, Allen B. Jetmore, Jerry E. Foote, L. Kirk ArnoldAbstract:PURPOSE An alternative approach to anal Bowen’s disease was investigated. The use of topical 5 percent 5-Fluorouracil for large lesions and surgical excision of small lesions were evaluated. METHODS A prospective study was undertaken for anal Bowen’s disease in 11 patients over a six-year period. Before therapy all patients underwent anal mapping biopsy and colonoscopy. For one-half circumferential disease or greater, patients underwent topical 5 percent 5-fluorouacil therapy for 16 weeks. For smaller involvement, wide surgical excision was performed. All patients underwent anal mapping biopsy one year after completion of therapy. RESULTS Of 11 patients, 8 (5 male) received 16 weeks of topical 5 percent 5-fluorouacil therapy. Three patients (3 female) underwent surgical excision for localized disease. All but one patient, who was HIV positive, were free of Bowen’s disease one year after completion of therapy. One patient underwent total excision of a residual microinvasive squamous carcinoma after circumferential Bowen’s dis-ease had resolved. One patient received eight additional weeks of topical 5-fluorouacil therapy for incomplete resolution. All patients were followed yearly, with a mean follow-up of 39 months and a range of 12 to 74 months. There have been no recurrences. There were no long-term side effects or morbidity from topical 5-fluorouacil or local excision. All colonoscopies were normal. CONCLUSION Topical 5 percent 5-fluorouacil therapy is a safe and effective method to treat anal Bowen’s disease. Wide local excision is appropriate for smaller, isolated areas of disease. Anal Bowen’s disease was not associated with colonic or other neoplasms.
-
Topical 5-Fluorouracil in the Management of Extensive Anal Bowen’s Disease: A Preferred Approach
Diseases of the Colon & Rectum, 2005Co-Authors: Bruce D. Graham, Allen B. Jetmore, Jerry E. Foote, L. Kirk ArnoldAbstract:PURPOSE An alternative approach to anal Bowen’s disease was investigated. The use of topical 5 percent 5-Fluorouracil for large lesions and surgical excision of small lesions were evaluated. METHODS A prospective study was undertaken for anal Bowen’s disease in 11 patients over a six-year period. Before therapy all patients underwent anal mapping biopsy and colonoscopy. For one-half circumferential disease or greater, patients underwent topical 5 percent 5-fluorouacil therapy for 16 weeks. For smaller involvement, wide surgical excision was performed. All patients underwent anal mapping biopsy one year after completion of therapy. RESULTS Of 11 patients, 8 (5 male) received 16 weeks of topical 5 percent 5-fluorouacil therapy. Three patients (3 female) underwent surgical excision for localized disease. All but one patient, who was HIV positive, were free of Bowen’s disease one year after completion of therapy. One patient underwent total excision of a residual microinvasive squamous carcinoma after circumferential Bowen’s dis-ease had resolved. One patient received eight additional weeks of topical 5-fluorouacil therapy for incomplete resolution. All patients were followed yearly, with a mean follow-up of 39 months and a range of 12 to 74 months. There have been no recurrences. There were no long-term side effects or morbidity from topical 5-fluorouacil or local excision. All colonoscopies were normal. CONCLUSION Topical 5 percent 5-fluorouacil therapy is a safe and effective method to treat anal Bowen’s disease. Wide local excision is appropriate for smaller, isolated areas of disease. Anal Bowen’s disease was not associated with colonic or other neoplasms.
